| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 14,391 | 21,196 | ||
| General and administrative | 4,775 | 5,880 | ||
| Total operating expenses | 19,166 | 27,076 | ||
| Loss from operations | -19,166 | -27,076 | ||
| Interest income | 342 | - | ||
| Change in fair value of warrant liability | -2,099 | - | ||
| Other expense, net | -2,011 | - | ||
| Total other income, net | 430 | - | ||
| Net loss and comprehensive loss | -18,736 | -26,700 | ||
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -1.13 | -1.74 | ||
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -1.13 | -1.74 | ||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares) | 16,635,784 | 15,333,962 | ||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) | 16,635,784 | 15,333,962 | ||
Jasper Therapeutics, Inc. (JSPR)
Jasper Therapeutics, Inc. (JSPR)